Lung Cancer

W. Victoria Lai, MD, discusses the results of the phase III CASPIAN trial in small cell lung cancer.

Michael D. Offin, MD, discusses ongoing research focusing on some of the less-common targetable mutations in non–small cell lung cancer.

We traveled to Salt Lake City, Utah, for a State of the Science Summit™ on Non–Small Cell Lung Cancer, which featured insights from the University of Utah and Intermountain Healthcare.

Khaled A. Hassan, MD, MS, discusses the results of the FLAURA trial, which compared osimertinib with first-generation TKIs in patients with EGFR-mutant metastatic non–small cell lung cancer.

Hossein Borghaei, DO, MS, highlights pivotal trials examining chemoimmunotherapy in metastatic nonsquamous non–small cell lung cancer, ongoing research efforts, and exciting biomarkers on the horizon.

Gregory M. M. Videtic, MD, CM, FRCPC, discusses ongoing developments with immunotherapy in stage III non–small cell lung cancer.

Katie Kerrigan, MD, discusses sequencing challenges in the treatment of patients with ALK-positive non–small cell lung cancer.

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Tony S. K. Mok, MD, BMSc, FRCPC, discusses overall survival from the phase III ALEX trial in ALK-positive lung cancer.

Edward S. Kim, MD, discusses how the use of immunotherapy has resulted in a paradigm shift in advanced nonsquamous non–small cell lung cancer and the steps that are being taken to broaden its use in clinical practice.

Katie Kerrigan, MD, discusses remaining challenges in the treatment of patients with ROS1-positive non–small cell lung cancer.

W. Victoria Lai, MD, discusses the impact immunotherapy has had in the management of patients with extensive-stage small cell lung cancer.

Shirish M. Gadgeel, MD, MBBS, Mary Lou Kennedy Research Professor in Thoracic Oncology, professor, Department of Internal Medicine, Division of Hematology/Oncology, co-leader, Thoracic Oncology Research Program, and associate director, Networking and Affiliated Centers, University of Michigan Medicine, discusses the results of the phase II/III BFAST trial in patients with ALK-positive lung cancer.

Gregory J. Riely, MD, PhD, discusses the current treatment landscape for ALK- and ROS1-positive non–small cell lung cancer.

Pradnya D. Patil, MD, FACP, discusses the implications of these trials and the growing role of immunotherapy in lung cancer.

Clarke A. Low, MD, discusses osimertinib (Tagrisso) versus dacomitinib (Vizimpro) in EGFR-mutant non–small cell lung cancer.

Timothy F. Burns, MD, PhD, discusses methods of identifying genetic alterations in lung cancer.

Nathan A. Pennell, MD, PhD, discusses the underutilization of genetic testing in lung cancer.

Khaled A. Hassan, MD, MS, discusses the use of EGFR TKIs in the treatment of patients with advanced EGFR-mutant non–small cell lung cancer and the emergence of osimertinib as the frontline standard of care.

The investigational KRAS G12C inhibitor MRTX849 demonstrated clinical activity in patients with non–small cell lung cancer and colorectal cancer.

Nathan A. Pennell, MD, PhD, discusses the actionability of advanced ALK-positive and ROS1-positive non–small cell lung cancer and the drugs that have emerged in the frontline and second-line settings.

The addition of durvalumab (Imfinzi) to platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy alone in patients with previously untreated metastatic non–small cell lung cancer.

Liza C. Villaruz, MD, discusses the data with immunotherapy in squamous non–small cell lung cancer.

Jeremy Segal, MD, PhD, discusses the use of next-generation sequencing for patients with lung cancer.

MCLA-128, an investigational bispecific HER2/HER3 antibody, demonstrated radiological and clinical responses in patients with metastatic pancreatic ductal adenocarcinoma and metastatic non–small cell lung cancer who have NRG1 fusions.